Targeting of tumor radioiodine therapy by expression of the sodium iodide symporter under control of the survivin promoter.
Huang
R
R
Department of Nuclear Medicine, National Key Discipline of Medical Imaging and Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.
Zhao
Z
Z
Ma
X
X
Li
S
S
Gong
R
R
Kuang
A
A
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D045744:Cell Line, Tumor; D003131:Combined Modality Therapy; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics*; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism / Q000532:radiotherapy / Q000628:therapy*; D011401:Promoter Regions, Genetic; D000077022:Survivin; D027981:Symporters / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D000099209:Sodium-Iodide Symporters
D051034:Inhibitor of Apoptosis Proteins; D007457:Iodine Radioisotopes; D000077022:Survivin; D027981:Symporters; D000099209:Sodium-Iodide Symporters; C107489:BIRC5 protein, human